Abstract 248P
Background
Over the past decade, a growing body of literature has elucidated the involvement of zinc homeostasis in tumor growth and progression. Herein, we present a bioinformatics-based study to evaluate the prognostic potential of zinc homeostasis-related genes in ccRCC.
Methods
The Human Genome Atlas Program (TCGA) was accessed to retrieve level 3 omics data and the corresponding clinicopathological variables. Differential expression of zinc homeostasis-related genes were considered statistically significant with a |Log2(fold change)| ≥ 1.5 and a P-value ≤ .01. The prognostic potential of selected genes was assessed using multivariate Cox logistic regression analysis. LinkedOmics was used to functionally annotate significantly co-expressed genes using KEGG terminology. Enrichment of the hallmarks of cancer gene sets was tested using gene set enrichment analysis (GSEA). Tumor immune microenvironment was explored using TIMER 2.0.
Results
A total of five significant differentially expressed genes were detected, including MT1G, SLC30A2, MT1F, SLC39A1, and MT1H. The latter being the only gene with a significant prognostic profile. High MT1H expression is associated with shortened overall survival (HR: 1.534, 95% CI: 1.140-2.064, P < .0048). Multivariate Cox logistic regression identified MT1H as an independent prognostic biomarker in ccRCC (HR: 1.392, 95% CI: 1.016-1.907, P < .04). MT1H co-expressed genes annotation highlighted the involvement of mineral absorption, ribosome, oxidative phosphorylation, and proteasome pathways. GSEA illustrated several alternations in epithelial-mesenchymal transition, inflammatory response,coagulation, complement, IL-6/JAK/STAT3 signaling, glycolysis, KRAS signaling, hypoxia, E2F targets, estrogen response, INF-γ signaling, and apoptosis. No clear trends or patterns were observed in tumor immune microenvironment in response to MT1H upregulation.
Conclusions
MT1H has been identified as a potential prognostic biomarker in ccRCC. Further experimental studies are needed to confirm the observed findings and to detect the exact molecular modulators involved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract